Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

M-106

Supelco

Mycophenolic acid solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C17H20O6
Numéro CAS:
24280-93-1
Poids moléculaire :
320.34
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Niveau de qualité

300

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

Concentration

1.0 mg/mL in acetonitrile

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

clinical testing

Format

single component solution

Température de stockage

−70°C

Chaîne SMILES 

COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O

InChI

1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+

Clé InChI

HPNSFSBZBAHARI-RUDMXATFSA-N

Informations sur le gène

human ... IMPDH1(3614) , IMPDH2(3615)

Catégories apparentées

Description générale

Assayed in therapeutic drug monitoring to ensure patients remain within the drug′s therapeutic range, mycophenolic acid is an immunosuppressant drug and the active metabolite of the prodrug mycophenolate mofetil. This analytical standard is suitable for LC-MS/MS applications including therapeutic drug monitoring and other clinical or diagnostic applications.

Application


  • Targeted Inhibition in Gastrointestinal Toxicity: Mycophenolic acid is employed in targeted inhibition studies of gut bacterial β-glucuronidases to alleviate gastrointestinal toxicity caused by mycophenolate mofetil. This application is crucial for enhancing patient outcomes in immunosuppressive treatments, showcasing its value in pharmaceutical research (Xia et al., 2024).

  • Synergistic Immunosuppression Therapy: The solution′s use in combination with low dose systemic immunosuppression to sustain vascularized composite allograft survival highlights its potential in transplant medicine. This research underscores the critical role of mycophenolic acid in developing effective immunosuppressive protocols (Feturi et al., 2024).

  • Development of Genetic Markers: Mycophenolic acid′s biochemical properties are utilized in the development of genetic markers within Yarrowia lipolytica, demonstrating its importance in genetic engineering and biotechnological advancements (Zhu et al., 2024).

  • Fungicidal Compound Discovery: The compound is used to derive fungicidal hydrazide lead compounds from sinapic acid and mycophenolic acid, illustrating its application in agricultural biochemistry and the development of new antimicrobial agents (Fang et al., 2023).

Notes préparatoires

This product contains an ampule of 1 mL, at a concentration of 1.0 mg/mL in acetonitrile.

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogrammes

FlameExclamation mark
GHS02,GHS07

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2 - Flam. Liq. 2

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

35.6 °F - closed cup

Point d'éclair (°C)

2 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

CD25 blockade for refractory polymyositis.
Nicolò Pipitone et al.
Clinical and experimental rheumatology, 31(3), 474-474 (2013-03-08)
David Wofsy et al.
Arthritis and rheumatism, 65(6), 1586-1591 (2013-03-27)
Clinical trials of therapies for lupus nephritis have used many different primary outcome measures, ranging from complete response to time to end-stage renal disease. The objective of this study was to compare several possible outcome measures, using data from a
Mycophenolate mofetil in severe lupus nephritis: should post hoc analyses change treatment patterns?
Jonathan J Hogan et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 61(5), 692-693 (2013-04-16)
E Kieslichova et al.
Transplantation proceedings, 45(2), 770-777 (2013-03-19)
The diagnosis of sepsis is difficult in immunocompromised patients owing to their modified response to infection. Our experiment in minipigs was designed to compare responses to sepsis between experimental groups of septic minipigs with and without immunosuppression. Minipigs with identical
L25. Medical treatment of subglottic stenosis in granulomatosis with polyangiitis (Wegener's).
Paul A Monach
Presse medicale (Paris, France : 1983), 42(4 Pt 2), 575-576 (2013-03-05)
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique